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In recent years experimental data have indicated that low-energy proton beam radiation
might induce a difference in cellular migration in comparison to photons. We therefore set
out to compare the effect of proton beam irradiation and X-rays on the survival and long-
term migratory properties of two cell lines: uveal melanoma Mel270 and skin melanoma
BLM.
Materials and methods
Cells treated with either proton beam or X-rays were analyzed for their survival using clono-
genic assay and MTT test. Long-term migratory properties were assessed with time-lapse
monitoring of individual cell movements, wound test and transpore migration, while the
expression of the related proteins was measured with western blot.
Results
Exposure to proton beam and X-rays led to similar survival but the quality of the cell colonies
was markedly different. More paraclones with a low proliferative activity and fewer highly-
proliferative holoclones were found after proton beam irradiation in comparison to X-rays. At
20 or 40 days post-irradiation, migratory capacity was decreased more by proton beam than
by X-rays. The beta-1-integrin level was decreased in Mel270 cells after both types of radia-
tion, while vimentin, a marker of EMT, was increased in BLM cells only.
Conclusions
We conclude that proton beam irradiation induced long-term inhibition of cellular motility, as
well as changes in the level of beta-1 integrin and vimentin. If confirmed, the change in the
quality, but not in the number of colonies after proton beam irradiation might favor tumor
growth inhibition after fractionated proton therapy.
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Introduction
Proton beam radiation is used to treat malignancies because of its superior biophysical proper-
ties concerning dose deposition in tissues compared to photon radiation [1]. In contrast to the
widely accepted view, that the two types of radiation exert similar biological effects in tissues,
with the relative biological effectiveness of 1.1, several intriguing differences between low-
energy proton beam and photon irradiated tumor cells have been reported. For example,
homologous recombination was more significant for proton beam induced DNA damage [2].
High-LET proton beam irradiation caused cluster DNA damage with higher complexity with
increasing LET [3], but low-LET proton beam caused similar DNA damage to photon irradia-
tion [4]. Other differences were found in the level of the production of free radicals, cell cycle
inhibition and apoptotic signaling [5]. In vitro treatment of tumor cells with a proton beam
resulted in a higher percentage of apoptotic cells when compared to photon radiation [6].
Additionally, differences were observed in cell cycle regulation: a high-LET proton radiation
induced a G2 phase arrest which was noticeably longer and harder to resolve in comparison to
similar doses of photon radiation [7]. This was not seen for low-LET proton radiation [8].
Radiation may also affect the formation of metastasis, including cell detachment from the
primary tumor, migration along the extra-cellular matrix (ECM), degradation of the basement
membrane, and intravasation into the blood or lymphatic vessels [9]. Tumor cell-migration
itself is a multistage process which depends on various factors such as proteinase activity
[10,11], the cytoskeleton organization of the migrating cells [12] and adhesion to the ECM
mediated by receptors such as integrins. Radiation may affect many of these steps, and a differ-
ential influence of proton and photon radiation has been suggested [5].
As proton beam therapy as well as radio-active plaque therapy are mainstays in the treat-
ment of uveal melanoma, we wondered how these different approaches affected melanoma
cells. We therefore studied the long-term effects of sublethal doses of proton beam irradiation
and of photon treatment on the migratory properties of uveal melanoma and metastatic
human melanoma skin cells. We tested cellular survival, motility and the level of β1-integrin
and vimentin after proton beam and photon irradiation and showed that proton beam, but
not photon irradiation, inhibited cellular rectilinear motility and changed heterogeneity of col-
onies. These effects were observed at long-term after treatment.
Materials & methods
Cell culture
We used Mel270, a primary human uveal melanoma cell line [13], and BLM, a cell line derived
from the lung metastases of skin melanoma [14]. Both cell lines were cultured at 37˚C, 5%
CO2 in RPMI media (Sigma-Aldrich, St. Louis, MO), supplemented with 10% fetal bovine
serum (Biological Industries, Cromwell, CT) and penicillin/streptomycin (Polpharma,
Poland). The Mel270 cells were a gift from prof. M. Jager from Leiden University (The Nether-
lands) and BLM cells from Dr G.N.P. van Muijen, Department of Pathology, Radboud Univer-
sity Nijmegen Medical Centre, Nijmegen (The Netherlands). The cells were passaged at 70–
80% of confluence every 5–6 days, so that the 4th passage was at day 20 post-radiation and the
7th passage was at day 40.
Irradiation
Cells irradiations with X-rays and high energy protons were performed at the Institute of
Nuclear Physics, Polish Academy of Sciences (IFJ PAN), Cracow, Poland. For X-ray irradia-
tion Phillips MCN-323 tube at the voltage of 250 kVp and the dose rate of 1.8 Gy/min was
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applied. The beam filtered with 4 mm beryllium and additional 1 mm of brass. Dosimetry was
performed using the PTW TM31013 ionization chamber with PTW UNIDOS electrometer,
calibrated in the secondary standard laboratory at the Central Office of Measures in Warsaw,
Poland. Cell cultures were irradiated in Eppendorf tubes placed on the surface of the PMMA
phantom, Eppendorf’s wall thickness was sufficient to compensate for the build-up effect. Pro-
ton beam irradiation took place at the Cyclotron Centre Bronowice at IFJ PAN. The 230 MeV
proton beam produced at the IBA Proteus C-235 cyclotron [15] and degraded at the energy
selector to the 70 MeV was delivered to the eye treatment room and mechanically formed
using a set of scaterers and energy modulator at the eye irradiation unit. Fully modulated pro-
ton beam with energy 61 MeV (31.5 mm range in water) collimated to the 40 mm lateral diam-
eter has been used for irradiation. During the irradiation the doses 1, 3, or 5 Gy have been
delivered with dose rate of 1 Gy/min, 2 Gy/ min and 6.6 Gy/min, respectively. At the center of
cell container position i.e. at the depths 15.8 mm of the SOBP the calculated Continues Slow-
ing Down Approximation (CSDA) dose averaged LETd was 2.8 keV/μm. Beam dosimetry was
performed according to the TRS-398 protocol recommended by International Atomic Energy
Agency [16] using a reference dosimeter consisting of a PTW TM31010 semiflex ionization
chamber and a PTW UNIDOS Webline electrometer (PTW, Freiburg, Germany). The dosim-
eter set was calibrated at the IFJ PAN at Theratron 780 60Co treatment unit. Cells were irradi-
ated in the Eppendorf tubes positioned orthogonally to the direction of the proton beam using
the dedicated phantom made out of PMMA. Cells were transported on ice between the facili-
ties, including the untreated control.
Clonogenic cell survival assay
The number of cells seeded into 6 cm diameter dishes was adjusted for each dose to achieve
the optimal number of colonies after radiation. The experiment was performed three times
and three replicate plates were seeded for each group in every repetition. For BLM and Mel270
cells alike, 100 (control), 300 (1 Gy), 500 (3 Gy) and 700 (5 Gy) cells were used in the case of
proton beam radiation and the numbers of seeded cells for X-rays were 100 (control), 200 (1
Gy), 500 (3 Gy) and 700 cells (5 Gy). The plates were incubated for 2 weeks and then the cells
were fixed and stained with Giemsa stain (Sigma-Aldrich, St. Louis, MO). The colonies formed
were counted, with minimum 50 cells/colony, and PE (plating efficiency) and SF (surviving
fraction) were evaluated. The colonies were divided into three groups according to their size
determined as holo-, mero-, and paraclones, as described earlier [17]. The number of cells in
colonies were: (i) 2500–6000 for holoclones, (ii) 500–2500 for meroclones and (iii) <500 for
paraclones.
PE ¼
Number of colonies counted
Number of cells plated
 100 ð1Þ
SF ¼
PE of treated sample
PE of control
 100 ð2Þ
RBE (Relative Biological Effectiveness) was calculated as the ratio of the absorbed dose of
reference radiation (X-rays) to the absorbed dose of radiation being researched (proton beam)
which causes the same biological effect (37% of cells that survived treatment).
MTT assay
The metabolic activity of Mel270 and BLM cells was measured with tetrazolium dye MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The cells were seeded into
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24-well plates (104 cells per well), and cell numbers were determined each day during the first
five days directly after irradiation and at 20 and 40 days post-treatment. Cells were supple-
mented with 10% of MTT (Sigma-Aldrich, St. Louis, MO) stock solution (0.5 mg/ml) and
incubated for 2.5 hrs. The MTT formazan crystals that formed were dissolved in DMSO
(Avantor, Poland) and methanol (Avantor, Poland) solution (1:1). Absorbance was measured
at a wavelength of 560 nm with the Tecan GENios Plus plate reader (Tecan, Switzerland).
Cell migration
Time-lapse monitoring of individual cell movements was used as an indicator of cellular
migration properties. The individual trajectories of cells were assessed 20 days (4th passage)
and 40 days (7th passage) after irradiation in both cell lines. Cells were plated at a density of 72
cells/mm2. After 48 hours the migration of cells was recorded at 37˚C for 10h, at 10 min inter-
vals. The trajectories of individual cells were evaluated from the changes in cell centroid loca-
tion, as described previously [18]. For each cell, the following variables were determined [19]:
(i) average speed of cell movement, i.e. the total length of cell trajectory/time of recording; (ii)
the total length of cell displacement (μm), i.e. the distance from the starting point direct to the
cell’s final position. The value of CME (Coefficient of Movement Efficiency) was calculated as
the ratio of the total cell displacement to the total length of cell trajectory. For each value, 50
cells were analyzed from 3 different wells.
Wound healing assay
The cells were plated onto 6-well plates (2.5 x 104 cells per well) at 20 (4th passage) and 40 (7th
passage) days and the assay was performed on the third day after seeding. A wound (scratch)
was made with a sterile tip. Pictures of the wound were taken at time point 0 h and 9 h. The
wound area was analyzed using ImageJ v.1.43U (Wayne Rasband, National Institute of Health,
USA) and the percentage of wound healing was calculated.
Invasion assay
Cell invasion was assessed with Boyden Chambers (8.0 μm pore size, Falcon, NY, USA) in
24-well plates. Cells (104) were put onto the upper surface of chambers. Chambers were incu-
bated at 37˚C for 48 h, at which time the number of cells at the bottom of the wells were
counted and the percentage of cells that invaded through the membrane was established.
Western blot
Cell monolayers were lysed in lysing buffer containing 1M Tris-HCl (pH 7.5), 3M NaCl,
NP4O, distilled water, a protease inhibitor cocktail (Roche, Switzerland), PMSF and sodium
orthovanadate. Cells were centrifuged at 13 000 RPM, 4˚C. The amount of protein was mea-
sured using the Bradford assay [20] and stored at -80˚C until used. Equal amounts of protein
(20 μg) were run on Bolt1 Bis-Tris Plus gels (Invitrogen, Thermo Fisher Scientific) and trans-
ferred to a nitrocellulose membrane using iBlot1 Dry Blotting System (Invitrogen, Thermo
Fisher Scientific). The membranes were blocked with 5% skim milk in a TBS buffer with 1% of
Tween 20 for 1h and incubated with primary antibodies against vimentin (D21H3) (Cell Sig-
naling Technology, MA, USA) and β1 integrin (Cell Signaling Technology, MA, USA) at 4˚C
overnight. Membranes were washed 3 times in TBS and incubated with suitable secondary
antibodies and then washed 3 times in TBS. Signals were detected using LumiGLO1 chemilu-
minescent substrate (Cell Signalling Technology, Danveers, MA).
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Statistical analysis
Statistical analysis was carried out using Statistica v12 (StatSoft. Inc.). Since we compared
more than three experimental groups, significance was determined by one-way analysis of var-
iance (ANOVA) after evaluation of homogeneity of variances with Levene’s Test. The differ-
ences were considered to be statistically significant at probability levels of p<0.05, p<0.01 and
p<0.001.
Results
Cell survival after proton and photon irradiation
To compare the effects of radiation between uveal and skin melanoma cells, their radiosensi-
tivity was determined using a clonogenic test after the two radiation qualities. A similar pattern
of dose dependence of survival fraction (SF) in the clonogenic test was seen for both cell lines
tested (Fig 1A and 1B). The Relative Biological Effectiveness (RBE) calculated for 37% of SF
was very close, 1.1 for Mel270 and 1.13 for BLM. This is exactly the same value as that accepted
for clinical proton radiotherapy [21].
Fig 1. Clonogenic assay of cell survival of Mel270 (A) and BLM (B) cells, treated with proton beam (■)
or X rays (●). Representative images of colonies are presented at S1 Fig. Cell were seeded immediately after
radiation. Mean values with SEM, *p<0.05; **p<0.001. RBE values were determined from a linear-quadratic
model and were 1.10 for Mel270, and 1.13 for BLM cells. (C–E) Three types of colonies formed by Mel270 (C)
and BLM (D) cells in two weeks after irradiation with 1–5 Gy of proton beam or X-rays, determined as the
percentage of the total number of colonies. Mel270 and BLM cells form three types of colonies described as
holo-, mero- and paraclones (E). Holoclones are large, packed colonies displaying heterogeneity, which are
believed to be derived from cancer initiating cells; meroclones are putatively derived from transit-amplifying
cells and paraclones are loosely packed cells, derived from differentiated cells [17].
https://doi.org/10.1371/journal.pone.0186002.g001
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To assess cell viability MTT assay was performed to evaluate the metabolic activity of cells
directly after proton beam and X-ray radiation, as well as 20 and 40 days post-irradiation. The
long-term time-points were the same as in the migration activity tests. Mel270 showed higher
sensitivity to proton beam radiation than to X-rays in the first five days directly after treatment
(S2 Fig). At the later time-points of 20 and 40 days the metabolic activity of cells was not
affected (S3 Fig).
Irradiation changed heterogeneity of cellular colonies
According to the literature [17] we divided them into three groups: holo-, mero-, and para-
clones (Fig 1C–1E). The largest holoclones, containing between 2500–6000 cells, are described
as displaying heterogeneity and as derived from cancer-initiating cells, middle sized mero-
clones (500–2500 cells) are probably derived from transit-amplifying cells and the smallest
paraclones (<500 cells) are loosely packed cells, derived from differentiated cells [17]. As the
growth time of these colonies was 14 days, we estimated the average doubling time for each
type of colonies. For holoclones the doubling time was 26–29 h, meroclones 29–33 h, and for
paraclones 38 h, which reflected substantial differences in their proliferative capacity.
Non-treated primary Mel270 cells formed similar numbers of holo-, and meroclones with a
small number of paraclones (7.6%) (Fig 1C). In contrast, BLM cells developed a similar num-
ber of all clone types (Fig 1D). Both proton beam and X-rays reduced the number of holo-
clones in both cell lines substantially. However, proton beam caused a decrease in the number
of holoclones from approx. 45% to 4% in Mel270 (all doses) and from 35% to almost none in
BLM cells (0.38% for 1 Gy), forming paraclones instead. In contrast, X-ray irradiation resulted
in considerable formation of holoclones after 1 and 3 Gy in Mel270 (from 45% to 34% and
24.6%, respectively) as well as in BLM cells (from 35% to 15.6% and 5.6%, respectively). The
number of paraclones increased in a dose-dependent manner up to 67.5% for Mel270 and 78%
for BLM cells. These results show the heterogeneity of both cell line populations and suggest
that both types of irradiation shift the formation of colonies from holoclones (highly prolifer-
ative) to paraclones (less proliferative activity), even though the overall resulting surviving
fraction, calculated from the total number of colonies, is similar for both types of radiation.
Proton beam radiation inhibited the motility of cells and changed their
direction of movement
Long-term irradiation effects were compared for both radiation qualities in Mel270 and BLM
cells. An analysis of Mel270 time-lapse recordings (S4 Fig) revealed inhibition of motility at 20
days after proton beam radiation (Fig 2), at reduced values of Speed (71–79%) and Displace-
ment (47–68%). The CME (coefficient of movement efficiency) values were also reduced for
all doses. Reduced CME suggests a change in the direction of movement. The lower the CME,
the more cells move in circles rather than in a straight line. The motility of Mel270 cells, at 40
days after treatment with proton beam radiation, was inhibited to 71.2% of control, with a
stronger effect after 5 Gy (Speed 35.3%; Displacement 52%), which translates into an increase
in CME for 5 Gy. Therefore, the overall motility of uveal melanoma cells was inhibited at 40
days as well, but without the impact on the direction of cell movement.
Irradiation of cutaneous melanoma BLM cells led to slightly different results (Fig 3). Fol-
lowing proton beam irradiation a decrease in Speed values was seen, with lower cell Displace-
ment. This was reflected in CME, which decreased to 79–87% at 20 days and 64–79% at 40
days post-treatment and indicated less rectilinear movement. The direction of cell movement
was not changed after X-rays.
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In summary, proton beam irradiation inhibited motile activity in both cell lines. In the
uveal melanoma cell movement was reduced, whereas in a metastatic cutaneous BLM cell line
cell movement was more random.
Both types of radiation slowed down wound closure
Both types of radiation decreased the wound regrowth rate, although at different time scale in
the two melanoma cell types. The inhibition of wound closure at 40–80% of control was
Fig 2. Cellular migration properties of Mel270 cells treated with proton beam radiation or X rays.
Individual cell movements were evaluated at 20 days after irradiation (A, B, C) and at 40 days after
irradiation (D, E, F) and three parameters were calculated: ‘Speed’, i.e. average speed of cell movement;
‘Displacement’, i.e. the total linear length of the cell displacement from the starting point (μm) and CME
(coefficient of movement efficiency), i.e. the ratio of cell displacement to the cell trajectory length. Mean values
presented as percent of control; *p<0.05, **p<0.01, ***p<0.001.
https://doi.org/10.1371/journal.pone.0186002.g002
Fig 3. Cellular migration properties of BLM cells treated with proton beam radiation or X rays.
Individual cell movements were evaluated at 20 days after irradiation (A, B, C) and at 40 days after irradiation
(D, E, F) and were evaluated in terms of ‘Speed’, i.e. average speed of cell movement; ‘Displacement’, i.e. the
total linear length of the cell displacement from the starting point (μm) and CME (coefficient of movement
efficiency), i.e. the ratio of cell displacement to the cell trajectory length. Mean values presented as percent of
control; *p<0.05, **p<0.01, ***p<0.001.
https://doi.org/10.1371/journal.pone.0186002.g003
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observed in Mel270 cells at 40 days and in BLM cells at 20 days post-irradiation (Fig 4A and
4B). Some inhibition was also seen for BLM cells treated with 3 and 5 Gy of X-rays. What is
more, the doubling time for the cell population of each experimental group was at least 30 hrs,
therefore the assay results were not affected by proliferation.
Cell invasion
The transmigration of cells through Boyden chambers (pore 8 μm) was related to the control
seeded without membrane and presented as the percentage of the non-treated control cells in
Fig 4C for Mel270 and in Fig 4D for BLM. In both proton beam treated cell lines, a decrease in
transmigration was seen, especially at 40 days post-irradiation. In contrast, a lower number of
X-ray irradiated cells was only observed at 20 days for Mel270 cells, but the numbers were not
statistically significant.
Irradiation decreased the level of β1-integrin
We performed WB analysis for integrin β1, which is involved in metastasizing and known to
decline after irradiation. Both types of irradiation strongly suppressed integrin β1 in Mel270
cells (Fig 5A) at 20 days post-treatment, the values ranged between 18%–40% and 10%–12%
for proton beam and X-rays respectively. At 40 days the cells showed an increase in their
β1-integrin level, although it still remained below the control level (50%-69%). In contrast, in
BLM cells (Fig 5B) the lowering of β1-integrin was seen only after 5 Gy at 20 days.
Fig 4. Wound healing assay conducted for Mel270 (A) and BLM (B) cells, and cell invasion assay for
Mel270 (C) and BLM (D). Both assays were performed 20 and 40 days post treatment with proton beam or X
rays. For wound healing test cell confluent monolayers were wounded with a pipette tip and images of the
wound closure were taken after 9 hours of incubation. For each of two time-points 15–20 images were
captured. Bars present the wound healing percentage normalized to control. *p<0.05; **p<0.01, ***p<0.001.
Cell invasion was assessed by measuring the transpore migration with Boyden chamber assay (not coated,
pore size 8 μm). Mean values in each group show the percentage of cells that migrated through the
membrane in relation to control seeded in the well without a membrane. Values presented as the % of control.
Mean ±SEM; *p<0.05.
https://doi.org/10.1371/journal.pone.0186002.g004
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BLM cells show a higher expression of vimentin after irradiation
No significant differences in vimentin, one of the markers for epithelial-mesenchymal transi-
tion (EMT), were found in Mel270 cells (Fig 5C) after irradiation. However, BLM cells (Fig
5D) treated with a proton beam displayed an increase in the protein level of between 143 and
162% at 20 days and between 163 and 214% at 40 days after irradiation. The increase was also
observed after X-rays at 20 days following treatment, especially in the case of 3 Gy (263%).
Nevertheless, at 40 days the vimentin expression decreased approximately to the control level.
Discussion
The comparison of the effects of two radiation qualities on melanoma cells showed distinct dif-
ferences in the colonies generated as well as long-term migratory properties. Despite the fact
that the two melanoma lines tested were of a different origin (uveal and cutaneous), in both of
them the proton beam, but not photon radiation, caused the inhibition of actively proliferating
cells and long-term motility inhibition. As we compared long-term effects, we used sublethal
doses of two types of radiation. These sublethal doses may be significant in fractionated ther-
apy or in combination therapies involving radiation treatment. What is more, we have to
Fig 5. Integrin β1 (A, B) and vimentin (C, D) protein expression assessed with Western Blot in Mel270
(A, C) and BLM (B, D) cells treated with different doses (1, 3, 5 Gy) of proton beam or X rays. Cells were
lysed 20 and 40 days after irradiation. (E) 20 μg of protein was applied per well. Control of untreated cells was
set to a 100%. Chemiluminescent evaluation of 3 independent Western blots of cell lysates was shown as a
mean of the percentage of the control and SEM. *p<0.05; **p<0.01; ***p<0.001.
https://doi.org/10.1371/journal.pone.0186002.g005
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consider margin of radiation during treatment. In spite of restrained area of the margin in the
case of proton beam irradiation, the tumor cells located within may contribute to formation of
metastatic lesions.
Low-LET proton beam irradiation inhibited actively proliferating cells
Our study showed that at 2 weeks post-treatment, overall clonogenic survival of both mela-
noma cells in vitro (Fig 1A and 1B) treated with either X-rays or proton beam irradiation is
very similar with fairly close RBE values. However, when we take into consideration the
subpopulations of clones featured (Fig 1) we observed a shift in the colonies formed after irra-
diation. This was manifested by a dramatic increase in the number of less active clones (para-
clones). These cells were physically present in the irradiated population and yet may have lost
their capacity for sustained proliferation. Such a state may be called a reproductive death, i.e. a
cell may be physically intact but has lost its ability to divide. Both kinds of irradiation, but espe-
cially proton beam irradiation drastically diminished the number of holoclones (containing
cancer stem-like cells [17]) in both cell lines. Such a drastic decrease in the number of holo-
clones, containing actively proliferating cells, with a concomitant increase in less active para-
clones might have a profound effect in vivo. Consequently, fractionated proton beam radiation
may result in a stronger inhibition of the tumor growth by decreasing actively the proliferating
cell population. This hypothesis requires further investigation.
It has to be pointed out that the cells studied were not synchronized in the cell cycle, so the
results observed are averaged over all cells in the population. What is more, we observed highly
heterogeneous cell populations in both cell lines.
Melanoma metastatic cell line HTB140 response to proton beam irradiation was intensively
studied [22,23]. It was shown that in comparison to gamma-rays, proton beam radiation
induced more apoptotic cells, for doses ranging from 8 to 24 Gy [23]. In our study, we have
focused on sublethal doses of radiation 1–5 Gy and observed slightly lower metabolic activity
and decreased number of highly proliferative clones (S2 Fig and Fig 1).
Relative biological effectiveness of proton beam was widely studied depending on such fac-
tors as cell sensitivity, dose, LET, initial energy of the beam or the depth in SOBP [21,24,25].
RBE increases linearly with LET [26,27] and with α coefficient and decreases with increasing
(α/β)photons [28]. RBE values vary from 1.1 to 1.7 for 2 Gy per fraction [29,30] and can reach
even 2.84 at the distal end of SOBP for very radioresistant cells [31]. Nevertheless usually in
vivo studies show RBE at mid-SOBP approximately 1.1 ranging from 0.7 to 1.6 [27]. Such
increase in RBE is significant, for example, application of variable RBE resulted in an increase
of RBE weighted dose in the SOBP plateau by approximately 18% for both normal and tumor
human cells [32]. Several models for predicting the RBE for proton beam were developed
[24,33,34] and many authors postulate using RBE-weighted proton beam modulation, or LET-
painting in the clinic [26,30,32,35].
Low-LET proton beam irradiation inhibited cellular motility
At both long-term time-points an effect on cellular motility was seen. In Mel270 cells we
observed a major influence on the direction of movement, which was also paralleled in the
decreased ability of Mel270 cells to invade. In BLM cells the direction of cellular movement
was inhibited by the proton beam at 40 days, which also was accompanied by numerous filo-
podia generated by the cells. In contrast to Zheng et al. [36] presenting the stimulating effect
on the migratory and invasive potential of tongue squamous cell carcinoma at only 24 hours
post radiation, we have not detected an increase in the motility of melanoma cells treated with
X-rays at long term after irradiation.
Proton beam irradiation and melanoma cell migration
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Despite the inhibited motility, cell invasion ability was only slightly, or not at all affected by
radiation, therefore it could be supposed that cell elasticity in cell migration and invasion plays
a role. However, in our experimental setup, we did not use any chemoattractant in the trans-
migration test and only cells that went through the transpore and migrated to the well were
counted. There may have been cells that were attached to the other side of the membrane, so
we may have underestimated the number of cells.
Another evidence supporting the notion of proton beam radiation inhibiting cellular
migration was shown in the studies, where proton beam irradiation of tumor cells and normal
primary human lens cells resulted in down-regulation of MMP-2 and MMP-9 [37,38], there-
fore suggesting suppression of the cell migration. In contrast, photons led to the up-regulation
of MMP-2 as well as of MMP-9 [37]. Hence the proton beam was thought to restrain cell
migration while photons may have stimulated it.
Suspected switch of the phenotype
Another interesting observation is a dramatic loss of β1 integrin in Mel270 cells at only 20
days post-radiation. Considering the absence of substantial changes in cell morphology one
might speculate that the loss of β1 integrin may be compensated for with an increase in a dif-
ferent integrin. On the other hand, we did not see any changes in vimentin level in Mel270,
which may indicate that the cells did not undergo an EMT after irradiation. Radiation-induced
EMT was reported for example for colorectal cells [39]. Therefore, we postulate that Mel270
did not lose their epithelial phenotype as they display a strong connection with neighboring
cells and EMT alter the integrity of cell-cell junctions, which results in the loss of contact
between cells. In BLM cells, however, we observed only a slight loss of β1 integrin at 20 days
after proton beam with an increase of vimentin level, which may suggest some shift towards
EMT phenotype. Nevertheless, we need to consider the fact that these cell lines are of a differ-
ent origin. BLM cells are derived from lung metastasis of cutaneous melanoma, therefore they
have already gone through an EMT process, which is associated with an increase in vimentin
level.
Switching phenotypes between epithelial and mesenchymal was recently reported in skin
melanoma [40]. It was observed that melanoma cells of both proliferative and invasive popula-
tions were able to start a tumor in vivo, although the latter ones took a much longer time. How-
ever, in the end the tumors were comparable and it was suggested that the cells could switch
phenotypes in both directions [41]. Despite the fact, that the proliferating population of cells
may be the major contributor to the growth of a tumor, the phenotype switching mechanism
may be used to evade growth arrest, therefore to acquire resistance, as in the case of NSCLC,
where the authors observed a high level of vimentin and also ZEB1 and AXL1 [42]. In this con-
text, our results might be interpreted in such a way that sublethal doses of radiation lead to
switching, or shifting of the phenotype towards more mesenchymal, as we observed (i) pheno-
typic heterogeneity, (ii) changes in cell migration and direction of movement, (iii) differences
in β1 integrin and vimentin levels. For further investigation EMT- associated signaling path-
ways should be explored, especially the transcription factors regulating the activity of the E-
cadherin promoter and E-cadherin repressors and therefore the activity of the beta-catenin/
TCF4 complex, MAP/ERK and JAK/STAT3 pathways [40].
Further studies directions
Nevertheless we need to be aware of the complexity of the possible mechanisms underlying the
differences in response of melanoma cells to proton beam and photon irradiation. Apart from
EMT connected factors, many pathways and processes may be engaged in post-radiation
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changes in melanoma cells. As cell migration requires a coordinated adhesion contacts
between cells as well as cell-ECM (extracellular matrix) interactions, there is a variety of
intracellular and extracellular proteins such as integrins, cadherins and catenins, may have
been affected [43]. Another aspects are the signaling pathways such as MAPK and WNT.
MAPK pathway covers many kinase modules that convey extracellular signals to proteins
controlling essential cellular processes such as cell growth, proliferation, differentiation,
migration and apoptosis [44,45] and WNT signaling pathway is responsible for cell prolifera-
tion, migration and polarization [46]. Worth pursuing are the mechanisms of DNA damage
repair, as it was already shown that homologous recombination is more important in repairing
proton beam induced DNA damage [2] and that at the distal end of SOBP an increased com-
plexity of DNA lesions and slower repair kinetics was observed [4]. Even though the direct
consequences of proton beam radiation are being better understood each year, very little is
known about its long term effects. Epigenetic changes may be responsible for maintaining
post-radiation phenotype [47], and the presence of cancer stem cells may impact the post-radi-
ation long-term response [48]. Therefore in order to fully explain the mechanisms behind of
the difference between proton beam and photon radiation on melanoma cells further studies
are required.
Clinical relevance
As metastasis is the main reason of mortality of patients with both skin and uveal melanoma,
any treatment inhibiting migratory properties of cells would be of benefit in the clinic. Proton
beam therapy is used for treatment of uveal melanoma since 1975 and its results are compara-
ble to brachytherapy, with the mean local control over 95%, and rate of complications 7.7%
[49,50]. It may be speculated that if proton beam therapy indeed inhibits metastatic properties
of cells, higher survival of uveal melanoma patients treated with proton beam might be seen, at
least in the long term. However, it is not possible from the data presented in the literature, to
conclude unequivocally whether such difference exists. Lane et al. point out in their recent
analysis of a large cohort of UM patients treated with proton beam that 25-year cumulative
UM-related mortality was approximately 30% for proton beam therapy and 50% after enucle-
ation. For 125I brachytherapy, the COMS study report 12-year mortality for older patients with
large tumors also at 30% [51].
On the other hand, one may argue that the effect of radiation on the cellular migratory
properties is exerted at the time of treatment, when micrometastases are already present [52],
and therefore the overall survival might not be affected. Perhaps some more light onto the role
the migratory properties of uveal melanoma cells will in the future come from studies showing
the mortality dependence on the genetic status of the tumor [53] and from a better under-
standing of the development of UM metastases [54].
Conclusions
Our results indicate that there are several distinct differences between the effect of proton
beam irradiation and X-rays on the survival mechanisms and migratory properties of mela-
noma cells. Proton beam radiation inhibited cellular rectilinear motility and decreased invasive
potential in comparison to X-rays. β1 integrin level was decreased after both types of radiation
in uveal melanoma cells, and the level of vimentin increased in BLM, cutaneous melanoma
cells. An important observation is the change towards a less proliferative type of colonies gen-
erated after irradiation with a proton beam. If confirmed in an in vivo setting, this might have
profound implications for the increased efficacy of fractionated proton beam radiotherapy.
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Supporting information
S1 Fig. Representative images of colonies formed by Mel270 and BLM cells. The number of
seeded cells is shown in the upper right corner of each plate photo.
(TIF)
S2 Fig. MTT test showing metabolic activity of Mel270 cells (A, B) and BLM cell line (C,
D). Metabolic activity was estimated during the first five days directly after treatment (A, D)
with proton beam or X rays expressed as percent of control for each day. Mean values, with
SEM, #p<0.05; p<0.01; p<0.001.
(TIF)
S3 Fig. MTT test showing metabolic activity of Mel270 (A) and BLM (B) cell line after 20
days and 40 days post irradiation. It was expressed for each day as percent of control. Mean
values, with SEM, #p<0.05; p<0.01; p<0.001.
(TIF)
S4 Fig. Individual trajectories of 50 non-dividing Mel270 cells expressed as circular dia-
grams. Single line represent a single cell trajectory with initial point of each trajectory set at
the 0 point of the diagram. Cells were seeded 20 days after irradiation with proton beam or X-
rays. Cell movement was recorded for 10 hrs, with 10 min intervals. A representative transmit-
ted light image of the cells is to the right (magnification 200x).
(TIF)
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